CAMBRIDGE, Mass. — August 27, 2025 — Leads & Copy — Flare Therapeutics Inc. (FlareTx) will participate in investor conferences in September, including Citi’s 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, in Boston; Cantor Global Healthcare Conference 2025 on Friday, September 5, 2025, in New York; Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, in New York, featuring Douglas Manion and Daphne Karydas; and the Bank of America Healthcare Trailblazers Private Company Conference on Wednesday, September 17, 2025, in Boston.
Flare Therapeutics is focused on drugging transcription factors to unlock therapeutic potential. Its lead program, FX-909, is being developed for urothelial cancer. The second lead program, FX-111, is undergoing IND-enabling studies for metastatic castration-resistant prostate cancer.
Sarah McCabe, investorrelations@flaretx.com; media@flaretx.com
Source: Flare Therapeutics Inc.
